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Abstract  
 
Objectives: To evaluate efficacy of nutrition and physical activity interventions in the 
clinical management of paediatric non-alcoholic fatty liver disease (NAFLD). The 
prevalence of paediatric NAFLD continues to rise alongside childhood obesity. Weight 
loss through lifestyle modification is currently first-line treatment, although 
supplementation of specific dietary components may be beneficial. 
Methods: Medline, CINAHL, EMBASE, Scopus and Cochrane Libraries were 
systematically searched to identify randomised controlled trials (RCTs) assessing 
nutritional and physical activity interventions. Primary outcome measures were changes 
to liver biomarkers assessed by imaging, histology or serum liver function tests. Study 
quality was evaluated using the American Dietetic Association Quality Criteria Checklist. 
Results: Fifteen articles met eligibility criteria investigating nutritional supplementation 
(vitamin E [n=6], probiotics [n=2], omega-3 fatty acids [n=5]), dietary modification (low 
glycaemic load [n=1] and reducing fructose intake [n=1]).  No RCTs examining physical 
activity interventions were identified. Vitamin E was ineffective at improving alanine 
transaminase levels, while omega-3 fatty acids decreased hepatic fat content. Probiotics 
gave mixed results while reduced fructose consumption did not improve primary 
outcome measures. A low glycaemic load diet and a low fat diet appeared equally 
effective in decreasing hepatic fat content and transaminases. Most studies were deemed 
neutral as assessed by the American Dietetic Association Quality Criteria Checklist. 
Conclusion: The limited evidence base inhibits the prescription of specific dietary and/or 
lifestyle strategies for clinical practice. General healthy eating and physical activity 
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guidelines, promoting weight loss, should remain first-line treatment until high quality 
evidence emerges that support specific interventions that offer additional clinical benefit. 
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What is known: 
 The prevalence of paediatric non-alcoholic fatty liver disease (NAFLD) continues 
to rise alongside childhood obesity.  
 Weight loss through diet and lifestyle modification is currently first-line 
treatment, but difficult to achieve and sustain for many patients. 
What is new: 
 This review highlights the lack of high quality RCTs examining nutrition or 
physical activity interventions in paediatric NAFLD 
 There is insufficient evidence to recommend dietary supplementation (vitamin E, 
probiotics, omega-3 fatty acids) for all paediatric NAFLD patients 
 There is no evidence on which to base the type, frequency and duration of 
physical activity, which should be prescribed to children with NAFLD. 
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INTRODUCTION 
Non-alcoholic fatty liver disease (NAFLD) describes a spectrum of hepatic injury 
associated with the accumulation of fat in the liver in the absence of an inherited 
metabolic defect or exposure to toxins including alcohol. Childhood obesity is on the rise, 
and in western obese paediatric populations, NAFLD prevalence is now estimated to 
range from 36% (1) up to 80% (2) .  Due to a lack of pharmacological options for 
NAFLD treatment, lifestyle modification, targeting weight loss through reduced energy 
intake and increased physical activity, is currently recommended as the first line of 
treatment in both adults and children (3, 4).  However, there are currently no specific 
guidelines for the type of dietary (e.g. supplementation and/or restriction of specific 
nutrients) or physical activity modifications (type, frequency, length of activity) that 
should be prescribed to children with NAFLD (5). Paediatric lifestyle interventions for 
NAFLD management have ranged from intensive 1 month lifestyle interventions (6) 
resulting in significantly improved alanine or aspartate transaminase  (ALT and AST) 
levels, to 2-year interventions involving increased physical activity, nutrition education 
and behaviour therapy with supplementation (7-12) with varying impact on markers of 
liver function.  
With lifestyle modification central to NAFLD management, it is essential that 
effective strategies be communicated to patients and their families, incorporating specific 
evidence-based nutrition and physical activity recommendations. Therefore the first aim 
of this systematic review was to determine the strength of evidence available for 
nutritional and lifestyle modifications in paediatric NAFLD subjects. Specifically, using 
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stringent inclusion criteria, including only gold standard randomised controlled trials 
(RCTs), and critically appraising trial quality using the American Dietetic Association 
evidence analysis approach and quality criteria checklist (13). Then based on the current 
evidence, our second aim was to provide clinical guidance and insight to clinicians, 
dieticians and other health professionals as to whether specific dietary and physical 
activity guidelines should be advised for clinical management and/or prevention of 
paediatric NAFLD. 
 
METHODS 
This review was restricted to RCTs reporting the effects of nutrition and physical activity 
interventions on liver biomarkers in children diagnosed with NAFLD.   We accepted any 
definition of NAFLD for the purpose of this review.   
 Eligible studies included publications written in English from any country with 
human participants (<19 years of age) with a diagnosis of NAFLD. Studies assessing 
food groups, nutrient intake, nutritional supplements, weight loss and/or physical activity 
were included. Only study arms where medications were used as part of standard 
treatment, without a reported increase in dose, and where participants were receiving 
medication prior to the intervention were included.   There were no restrictions on the 
length of intervention or follow-up period. 
 Studies involving participants with late stage liver disease or conditions not 
commonly associated with NAFLD, and/or that influence dietary behaviour such as 
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coeliac disease and severe malnutrition, were excluded. Studies involving participant’s 
receiving enteral and/or parenteral nutrition were also excluded. 
 
Literature Search: 
Two independent researchers (SL, PSG) conducted separate literature searches to identify 
and appraise studies. Databases were searched from their inception until 18th January 
2016. Databases include Medline, CINAHL, EMBASE, Scopus and The Cochrane 
Collaboration Libraries. Search results were verified and discrepancies resolved by group 
discussion (SL, PSG, JBM, KHH). 
 The selected search terms included: (NAFLD OR “non alcoholic fatty liver 
disease” OR “non-alcoholic fatty liver disease” OR NAFL OR “non alcoholic fatty liver” 
OR “non-alcoholic fatty liver” OR NASH OR “non alcoholic steatohepatitis” OR “non-
alcoholic steatohepatitis”) AND (diet* OR nutri* OR food OR weigh* OR overweight 
OR obes* OR BMI OR “Body Mass Index” OR “physical activit*” OR exercis* OR 
fitness) AND (Child* OR P#ediat* OR Adolescen* OR infan*). Related MeSH headings 
were used in Medline, CINAHL, Scopus and Cochrane libraries.  Searches for EMBASE 
and Cochrane were modified to include the search terms pediat* OR paediat*.  An 
example of specific search strategy details is shown in Supplemental Digital Content 1, 
Table, http://links.lww.com/MPG/A993. 
 All articles were managed in a citation management software program (Endnote).  
All coding of articles for the first and second pass were completed using Endnote.  Any 
study published only in abstract format or unpublished reports were excluded from the 
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analysis. Titles and abstracts were evaluated against eligibility criteria.  Studies appearing 
to be eligible based on abstract were read in full.  Reference lists of eligible articles were 
hand-searched for additional articles that met the inclusion and exclusion criteria. 
Data Extraction and Study Quality: 
Data were extracted into Endnote independently by two researchers (SL and PSG) using 
an adaptation of the Cochrane Data Extraction Tool (14).  Data extracted from the articles 
included: study setting, study population, participant demographics and baseline 
characteristics, inclusion and exclusion criteria, diagnosis criteria for NAFLD, details of 
the intervention and control conditions and any co-treatments, study methodology and 
blinding, recruitment and study completion rates, outcomes and times of measurement 
and effect size. The same two researchers (SL and PSG) independently assessed the risk 
of publication bias and study quality using the American Dietetic Association Quality 
Criteria Checklist (13). Any discrepancies were discussed and resolved by consensus.  
This checklist includes ten validity questions based on the Agency for Health and 
Research Quality, Important Elements for Research Studies. These elements identify 
sound study design and execution. If most of the answers to the validity questions (6 or 
more) were ‘No’, the study was deemed ‘negative’; if the answers to questions 2, 3, 6 and 
7 did not indicate that the study was exceptionally strong, the report was deemed 
‘neutral’; and if most questions, including the four core questions with at least one 
additional question were answered ‘yes’, then the study was deemed ‘positive’ (13).  
Outcome Measures: 
The primary outcome measures included changes; degree of histological change (fat, 
inflammation or fibrosis), change in ultrasonic echogenicity, change in liver fat as 
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measured by MRI or change in  transaminases (ALT, AST or gamma-glutamyl 
transpeptidase (GGT)).   
 Considering the role of dyslipidaemia, insulin resistance (IR) and adiposity in 
NAFLD pathogenesis (4), secondary outcome measures included changes to markers of 
cardiovascular risk [HDL, LDL, triglycerides, total cholesterol], insulin resistance [2-
hour oral glucose tolerance testing (2-h OGTT), fasting insulin levels (FI), fasting 
glucose levels (FSG), fasting glucose or insulin ratio’s] and anthropometry [weight, BMI, 
BMI z-score and waist circumference (WC)]. Secondary outcome measures were only 
collected from eligible studies when available. 
 
RESULTS 
A total of 8441 records were derived from database searches. 1003 duplicates were 
removed, 3921 papers were excluded by title and 3402 by abstract.  Of the 114 articles 
reviewed in full, 5 articles were conference abstracts, 82 articles were not in a population 
of interest and 12 did not report on a primary outcome of interest (Figure 1).  Fifteen 
articles met the inclusion and exclusion criteria. Two of the eligible articles reported data 
from an extension of a RCT (9, 11).  Results from the initial trial and extension have been 
combined for the purpose of this review (excluding ADA quality checks) (8-11).   
 Overall, 821 individuals participated in 13 RCTs ranging in duration from 4 
weeks to 24 months (Table 1).  Of the studies that met eligibility criteria, 11 trials 
investigated nutrient or nutritional supplementation (vitamin E (7-9, 15, 16), probiotics 
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(17, 18) and omega-3 fatty acids (10, 11, 19-21)) and two assessed dietary modification 
(low glycaemic load diet (22) and a reduction of fructose intake (23)). 
Study Population Characteristics 
 Inclusion and exclusion criteria varied between studies; nine studies required 
participants to be classified as obese with a BMI centile over the 85th (17, 20, 23) or 95th 
(6, 15, 16, 18, 21, 22) centile for gender and age.  The mean/median BMI and BMI z-
score of participants in each study arm at baseline ranged from 24.4 to 34.7kg/m2 and 
2.01 to 3.44 respectively.  Jin et al. (23) and Alisi et al. (17) only included participants 
who identified as being of Hispanic (23) or Caucasian (17) descent respectively, while 
the remaining RCTs did not exclude participants based on ethnicity. 
Diagnosis of NAFLD 
 To meet eligibility criteria of this review, all participants required a confirmed 
diagnosis of NAFLD; however, diagnosis criteria varied between studies.  Seven trials 
required a more robust method of diagnosing steatosis or fibrosis based on histology, 
with six of these trials also measuring transaminases (7-9, 11, 17, 20); whereas five trials 
included participants with diagnosis of NAFLD via ultrasound (US) alongside elevated 
transaminases (6, 16, 18, 19, 21). Two studies (22, 23) made a NAFLD diagnosis using 
MRS whereas one study (15) based the NAFLD diagnosis on evidence of hepatic 
steatosis using ultrasound exclusively. Additionally, Alisi et al. (17) only included 
participants with diagnosed NASH based on histology. 
Vitamin E 
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Our search identified six studies prescribing vitamin E supplementation (6-9, 15, 16). The 
formulation and dosage of vitamin E varied between studies with Ackam et al. (15) and 
Wang et al. (6) failing to specify the formulation of vitamin E prescribed.  Nobili et al. 
(8, 9) prescribed alpha-tocopherol in conjunction with ascorbic acid while Vajro et al. 
(16) prescribed D-alpha-tocopherol acetate. 
Five studies noted a decrease in ALT levels post-intervention (6-9, 16) with no 
significant difference in overall decrease between intervention and control [16, 18, 21, 
22].  Conversely, Wang et al. (6) found that the decrease in ALT levels was greater in the 
intervention arm compared to the controls who received no lifestyle intervention.  Three 
studies measured changes to liver imaging post-supplementation.  Vajro et al. (16) and 
Akcam et al. (15) noted improvements to bright liver echogenicity whereas Wang et al. 
(6) noted no change in hepatic fat content measured with ultrasound after one month of 
supplementation. Two studies analysed histological changes post-intervention.  Nobili et 
al. (8, 9) noted that improvements to NAFLD activity score were similar between 
intervention and control groups whereas Lavine et al. (7) found that resolution of NASH 
was significantly greater among children treated with Vitamin E compared to a placebo 
(p=0.006).  
Probiotics 
Two RCTs in children were identified, evaluating the influence of either single 
strain (Lactobacillus rhamnosus strain GG) (18) or multistrain VSL#3 (17) probiotic 
supplementation on hepatic biomarkers.  Although Vajro et al. (18) reported no effect of 
lactobacillus rhamnosus strain GG on liver echogenicity, there was a significant decrease 
in average ALT variation in children treated with Lactobcaillus rhamnosus strain GG as 
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compared to placebo. Conversely, Alisi et al. (17) found that VSL#3 supplementation 
reduced the severity of steatosis as assessed by ultrasound. 
Omega-3 Fatty Acids 
In total, five studies investigating the effect of omega-3 fatty acid supplementation in 
children with NAFLD were identified. The dosage and formulation of omega-3 fatty 
acids varied between the studies, with concentrations ranging between 250mg and 
1300mg/day, while fish oil composition included DHA only (10, 11, 20) or a 
combination of DHA and eicosapentaenoic acid (EPA) (19).  Three studies used linoleic 
acid as placebo (10, 11, 20) while one study used sunflower oil containing omega-6 LC-
PUFA (19).  Boyraz et al. did not describe either the PUFA composition or placebo 
content (21).   
 All five studies used liver enzyme levels as an assessment of NAFLD severity 
post-intervention.  ALT (11, 19), AST (19) and GGT (19) levels were significantly 
reduced in intervention when compared to the placebo group while Boyraz et al. found 
no difference between intervention and placebo groups in ALT and AST reduction (21).  
All five studies used liver imaging as the method of detection post-intervention.  Pacifico 
et al. was the only study to use MRS as a primary outcome measure. One study 
prescribing two different concentrations of omega-3 DHA (250mg vs. 500mg) alongside 
placebo indicated that after 6 months of DHA supplementation, the risk of severe 
steatosis was reduced (250mg = OR 0.01, p<0.01 / 500mg = OR 0.04, p=0.01) with no 
difference in dosage effectiveness as assessed by ultrasound (10, 11).  Boyraz et al. 
showed decreased liver steatosis as assessed by ultrasound in PUFA group as compared 
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to the control group after 12 months of treatment (21).  Janczyk et al. did not observe any 
difference in degree of liver steatosis between omega-3 and placebo groups (19).  
Dietary Modification 
Two studies prescribing changes to dietary composition were identified with a total of 41 
participants in the intervention and control arms (22, 23).  Jin et al. (23) found that four 
weeks of reduced fructose consumption in an isocaloric diet did not improve hepatic fat 
content as measured by MRS. However, Ramon-Krauel et al. (22) found that a low GL 
diet in or a low fat diet improved hepatic fat content in both arms of the trial, with no 
significant differenced between the two groups after 6 months (p=0.76) as detected by 
MRS. 
 Both the low fat and low GI diets led to a decrease in BMI with no significant 
differences between the two groups (22), while Jin et al. reported no difference in body 
weight for either the fructose or glucose arms of the trial (23).  However, the glucose arm 
of the Jin et al. study demonstrated reduced fructose consumption significantly improved 
adipose IR (p=0.04) despite no change in overall BMI (23). Ramon-Krauel et al. showed 
both low fat and low GI diets showed improvements in ALT levels while the low fat 
group also showed significant improvements in insulin sensitivity (FI, HOMA).  
However, the low fat group also showed significant improvements in bot the waist 
circumference (p=0.02) and waist to hip ratio (p=0.01) after 6 months, which could 
contribute to these findings (22). 
Lifestyle Modification 
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 Notably, most trials recommended lifestyle modification as a co-intervention (7-
11, 15-17, 19-22).  The details and dietary targets guiding lifestyle modification were 
often limited, with three publications completely failing to outline the dietary and 
physical activity recommendations (7, 10, 19). Details of the interventions, their outcome 
measures and reported changes are in Table 1. No RCTs were identified which 
investigated the impact of exercise on hepatic biomarkers of children with diagnosed 
NAFLD. Four of the five studies reported reduced steatosis after supplementation with 
omega-3 fatty acids (10, 11, 20, 21) with the remaining study only reporting 
improvements in AST and GGT levels (19).   
Study Quality 
 In utilising the ADA Quality Criteria, we identified four positive, ten neutral and 
one negative article (Table 2).  The 11 articles deemed of ‘neutral’ or ‘negative’ quality 
were classified as such due to: unclear method of randomisation (6, 8, 15, 21-23); poor 
description of methodology (6, 8, 9, 15, 16, 19); unclear system of blinding (22); failing 
to measure effect size [excluding pilot studies] (6, 15, 16); failing to declare conflicts of 
interest (6, 8, 16) and no indication of funding source (9, 11).  Ackam et al. (15) violated 
statistical assumptions and based conclusions on findings that were not statistically 
significant.  Compliance to study protocols was poorly measured; pill count, pill diaries 
and/or patient interviews were only used in eight trials to measure participant adherence 
to supplementation regimes (8-11, 15, 19-21).  In addition, only one vitamin E study (16) 
assessed compliance to vitamin E supplementation via serum levels of vitamin E.  
Similarly three studies assessed compliance by blood docosahexaenoic acid (DHA) levels 
pre- and post-intervention (10, 11, 20).  Four trials assessed compliance with dietary 
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recommendations using objective nutritional assessment tools (9, 15, 19, 22) with 
findings reported in two publications (19, 22).  Weight loss was used to assess dietary 
compliance in three studies (8, 9, 16).  Compliance with supplementation 
recommendations or lifestyle modification was not measured by any means in two studies 
(6, 18). 
 
DISCUSSION 
The eligible RCTs for this systematic review include a variety of nutrition interventions 
for the management of paediatric NAFLD with considerable heterogeneity in study 
protocols and outcomes. Thirteen of the 15 eligible trials assessed the impact of various 
nutritional components or supplementation on NAFLD severity. Most notable were the 
differences in NAFLD diagnostic criteria and primary outcome measures utilized 
between the studies.  While diagnosis of NAFLD based on histology remains the gold 
standard, several of the studies included in this review were based on a NAFLD diagnosis 
from elevated transaminase levels, ultrasound or MRS. Abnormal liver function tests are 
a poor diagnostic tool, and have poor sensitivity and specificity for NAFLD with normal 
ALT levels commonly found in NAFLD patients and degree of elevation of 
transaminases poorly reflective of histological severity (24). Ultrasound is commonly 
used to assess for steatosis using echogenicity of the liver as it is time and cost effective, 
however, if levels of fat in the liver are low, or patients are morbidly obese (25), 
diagnosis may be missed. Additionally, MRS are more reliable non-invasive methods but 
are expensive, time consuming not commonly used in clinical practice (26). Furthermore, 
steatosis is not necessarily the problem at hand, but our inability to diagnose the more 
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significant conditions NASH and fibrosis. Therefore, until more robust data based on 
histologically diagnosed paediatric NAFLD patients with dietary supplementation are 
produced, caution should be applied when prescribing nutritional supplementation for the 
treatment of NAFLD. 
Vitamin E 
While six of the RCTs evaluated the role of vitamin E supplementation in 
NAFLD treatment, it is difficult to directly compare trials as a result of: differing doses 
and/or unclear formulations of vitamin E; supplementation of vitamin E in conjunction 
with other antioxidants; variable intervention periods; and poor reporting of study results.  
The high quality TONIC trial by Lavine et al. (7) found no significant differences in ALT 
levels, their primary outcome measure, between the intervention and control group after 
96 weeks of supplementation. However, the authors noted significant improvements in 
liver histology among participants with biopsy-proven NASH.  
 Furthermore, vitamin E supplementation may be beneficial in children with poor 
adherence to lifestyle recommendations.  Vajro et al. (16) stratified data based on 
compliance to lifestyle modification, using weight loss as an indicator of compliance.  
Normalisation of ALT was seen in control children who strictly adhered to lifestyle 
intervention and children who only complied with the supplementation regime with 
minimal adherence to dietary and physical activity recommendations.  As poor 
compliance with weight reduction initiatives is a widespread issue among overweight and 
obese paediatric populations (27), the evidence base for the utility of vitamin E 
supplementation as a targeted strategy in children with NAFLD with poor compliance to 
lifestyle recommendations should be strengthened.   
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Probiotic Supplementation 
 There is increasing understanding of the role of the gut microbiota in NAFLD 
pathogenesis. However, only two RCTs in children were identified, evaluating the 
influence of either single strain (Lactobacillus rhamnosus strain GG) (18) or multistrain 
VSL#3 (17) probiotic supplementation on hepatic biomarkers.  Whereas no effect of 
lactobacillus rhamnosus strain GG on liver echogenicity was found, in an ordinal logistic 
regression model, 4 months of VSL#3 supplementation reduced the risk of moderate and 
severe steatosis as assessed by ultrasound.  In addition, participants supplemented with 
VSL#3 experienced a significant decrease in BMI from a mean of 27.1 to 24.9 however 
there was no improvement observed in mean ALT levels.  The author’s credit the positive 
effects reported on fatty liver and body weight to VSL#3-dependent reversal of dysbiosis, 
but this was not measured directly. Furthermore, the RCTs at 8 and 16 weeks were of 
short duration, preventing assessment of the long-term effects of probiotic 
supplementation.  We note that long term follow up examining the effect of discontinuing 
probiotic supplementation is warranted in light of evidence showing resilience by the 
microbiome to short-term dietary interventions with rapid return to baseline composition 
observed (28). 
Omega-3 Fatty Acid Supplementation 
 Intakes of PUFAs, in particular omega-3 fatty acids, have been implicated in 
NAFLD pathogenesis, with deficiency believed to contribute to hepatic fat accumulation 
and the progression of steatosis to NASH.  We identified five RCTs testing omega-3 fatty 
acid supplementation in paediatric NAFLD patients. These were well-designed trials with 
three out of the five studies (10, 11, 20) considered positive for overall quality rating 
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based on the American Dietetic Association Quality Criteria Checklist.  However, again 
direct comparison of the studies is difficult given differences in the concentration and 
composition of omega-3 fatty acid supplements used and the variable treatment periods.  
Four of the studies reported reduced steatosis after supplementation (10, 11, 20, 21) with 
the remaining study only reporting improvements in AST and GGT levels (19).  Similar 
findings have been noted in a recent RCT conducted in adults, with a significant 
reduction in liver fat percentage in NAFLD patients supplemented with 4g DHA/EPA for 
15 to 18 months (29).  Interestingly, a study evaluating the consumption of fish and 
omega-3 fatty acids in children with NAFLD demonstrated very low intakes of fish, 
alongside low intakes of omega-3 fatty acids, which was associated with increased portal 
and lobular inflammation (30).   
Dietary Modification 
 Although lifestyle and dietary modification aimed at weight loss is the first-line 
treatment for NAFLD, we only identified two RCTs evaluating diet-based interventions.  
Ramon-Krauel et al. compared a low-GL diet to a low fat diet with authors noting no 
significant differences in diet effectiveness. However, significant reductions in ALT 
levels were observed in both low-GL and low fat diets (22).  Furthermore, despite the 
growing evidence implicating fructose in NAFLD pathogenesis, we only identified one 
study assessing fructose intake (31), based on high fructose beverages compared against 
equally high glucose beverages. Results ultimately noted no effect of reduced dietary 
fructose consumption on hepatic fat, as measured by MRS or liver enzymes. While 
eleven trials recommended, a co-intervention involving dietary modification only two of 
these used objective measures to assess participant compliance. In general descriptions of 
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the types of dietary modification recommendations made was poor and insufficient 
information regarding dietary measurement, participant compliance or the healthcare 
professionals involved was provided. Although there are clear challenges to measuring 
dietary intake, particularly in children and adolescents, reporting of dietary methods in 
line with recent recommendations for paediatric obesity interventions to assist with future 
meta-analysis should be encouraged for future studies (32).   
Physical Activity 
 Although a significant body of evidence in adults suggests that physical activity 
may influence NAFLD severity (33), we did not identify any RCTs assessing the impact 
of exercise on hepatic biomarkers in children diagnosed with NAFLD.  However, trials in 
obese paediatric populations (without NAFLD diagnosis per se) have demonstrated the 
positive effects of physical activity on steatosis as assessed by MRI (34, 35) or MRS (36, 
37). One cohort study investigated lifestyle modifications in 84 Italian children with 
biopsy proven NAFLD and prescribed a balanced, low calorie diet with moderate aerobic 
activity (38).  Results showed significant improvements in serum ALT and steatosis with 
a weight loss of over 20% body weight over a 1-year period.  The same group then went 
on to show lifestyle interventions with diet and physical activity induced weight loss and 
were associated with significant improvements in liver histology (9).  Twelve of the 
fifteen RCTs included in this review prescribed exercise recommendations as a co-
intervention. However, the type and duration of physical activity prescribed to 
participants was poorly described with little or no rationale to justify recommendations.  
Furthermore, only Janczyk et al. used an objective assessment tool to evaluate adherence 
to physical activity recommendations (19).  We therefore recommend that a high quality 
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RCT should be undertaken to assess the influence of physical activity on relevant clinical 
markers, such as LFTs and imaging techniques, in children with diagnosed NAFLD. 
Study Quality 
 While the subject of nutrition and physical activity management strategies in 
children with NAFLD was recently reviewed by Africa et al (39), the authors were were 
non-discriminant about the inclusion of non-randomised clinical trials and also included 
studies where children without a NAFLD diagnosis were included in the clinical 
population. In addition to our stringent inclusion criteria, one of the strengths of this 
systematic review was the use of the ADA Quality Criteria Checklist that provides an 
insight into the risk of bias for each study, and determines the quality rating for each 
study based on design. Overall, the majority of RCTs included in this review were 
evaluated as  ‘neutral’ quality; therefore the results of these studies should be interpreted 
with caution (13).  Based on our critique of the eligible studies it is apparent that future 
RCTs should aim to be more transparent in their reporting of diagnostic criteria and in the 
inclusion/ exclusion criteria used to recruit study participants.  Studies should complete a 
thorough assessment of participants’ characteristics and behaviours that may contribute to 
NAFLD or confound study results.  In addition, while dietary and physical activity may 
confound study results, adherence to lifestyle recommendations should be measured 
using an objective measure with results clearly reported. 
 
Conclusions 
Copyright © ESPGHAN and NASPGHAN. All rights reserved.
This systematic review has identified the heterogeneity of studies assessing dietary and 
physical activity interventions in paediatric NAFLD patients.  Findings from this 
systematic review suggest that vitamin E may be a possible treatment option in patients 
with biopsy proven NASH, or demonstrate poor compliance with lifestyle 
recommendations. Probiotic of omega-3 fatty acid supplementation may be a possible 
nutritional intervention to improved primary and secondary outcomes in children with 
NAFLD. Additionally, there is little evidence in children about the impact of physical 
activity on NAFLD management. Therefore, more high-quality RCTs should be 
completed to determine the type, frequency and duration of physical activity which 
should be prescribed to paediatric NAFLD population. At present, there is insufficient 
high quality evidence to prioritise a single approach for the effective management of 
paediatric NAFLD. Generalised lifestyle modification targeting weight loss through 
reduced energy intake and increased physical activity should remain the first line of 
treatment for paediatric NAFLD until additional high quality evidence is available. 
Copyright © ESPGHAN and NASPGHAN. All rights reserved.
 
REFERENCES 
1. Blachier M, Leleu H, Peck-Radosavljevic M, et al. The burden of liver disease in 
Europe: a review of available epidemiological data. J Hepatol 2013;58:593-608. 
2. Giorgio V, Prono F, Graziano F, et al. Pediatric non alcoholic fatty liver disease: 
old and new concepts on development, progression, metabolic insight and potential 
treatment targets. BMC Pediatrics 2013;13:40. 
3. European Association for the Study of the Liver . EASL-EASD-EASO Clinical 
Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 
2016;64:1388-402. 
4. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of 
non-alcoholic fatty liver disease: practice Guideline by the American Association for the 
Study of Liver Diseases, American College of Gastroenterology, and the American 
Gastroenterological Association. Hepatology 2012;55:2005-23. 
5. Alisi A, Nobili V. Non-alcoholic fatty liver disease in children now: lifestyle 
changes and pharmacologic treatments.  Nutrition 2012;28(7-8)722-6. 
6. Wang CL, Liang L, Fu JF, et al. Effect of lifestyle intervention on non-alcoholic 
fatty liver disease in Chinese obese children. World J of Gastroenterol 2008;14:1598-602. 
7. Lavine JE, Schwimmer JB, Van Natta ML, et al. Effect of vitamin E or metformin 
for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC 
randomized controlled trial. JAMA 2011;305:1659-68. 
8. Nobili V, Manco M, Devito R, et al. Effect of vitamin E on aminotransferase 
levels and insulin resistance in children with non-alcoholic fatty liver disease. 
Aliment Pharmacol Ther 2006;24(11-12):1553-61. 
9. Nobili V, Manco M, Devito R, et al. Lifestyle intervention and antioxidant 
therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. 
Hepatology 2008;48:119-28. 
10. Nobili V, Bedogni G, Alisi A, et al. Docosahexaenoic acid supplementation 
decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind 
randomised controlled clinical trial. Arch Dis Child 2011;96:350-3. 
11. Nobili V, Alisi A, Della Corte C, et al. Docosahexaenoic acid for the treatment of 
fatty liver: Randomised controlled trial in children. Nutr Metab Cardiovasc Dis. 
2013;23:1066-70. 
12. Reinehr T, Schmidt C, Toschke AM, et al. Lifestyle intervention in obese children 
with non-alcoholic fatty liver disease: 2-year follow-up study. Arch Dis Child 
2009;94:437-42. 
Copyright © ESPGHAN and NASPGHAN. All rights reserved.
13. Academy of Nutiriton and Dietetics. Evidence Analysis Manual. Steps in the 
Academy Evidence Analysis Process [Internet]. 2012 24 November 2015 24 November 
2015]. Available from: http://andeal.org/files/Docs/2012_Jan_EA_Manual.pdf. 
14. The Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of 
Interventions (Version 5.1.0) [Internet] 2011. Available from: 
http://handbook.cochrane.org/. 
15. Akcam M, Boyaci A, Pirgon O, et al. Therapeutic effect of metformin and vitamin 
E versus prescriptive diet in obese adolescents with fatty liver. Int J Vitam Nutr Res 
2011;81:398-406. 
16. Vajro P, Mandato C, Franzese A, et al. Vitamin E treatment in pediatric obesity-
related liver disease: a randomized study. J Pediatr Gastroenterol Nutr 2004;38:48-55. 
17. Alisi A, Bedogni G, Baviera G, et al. Randomised clinical trial: The beneficial 
effects of VSL#3 in obese children with non-alcoholic steatohepatitis. Aliment 
Pharmacol Ther 2014;39:1276-85. 
18. Vajro P, Mandato C, Licenziati MR, F, et al. Effects of Lactobacillus rhamnosus 
strain GG in pediatric obesity-related liver disease. J Pediatr Gastroenterol Nutr 
2011;52:740-3. 
19. Janczyk W, Lebensztejn D, Wierzbicka-Rucinska A, et al. Omega-3 Fatty acids 
therapy in children with nonalcoholic Fatty liver disease: a randomized controlled trial. J 
Pediatr 2015;166:1358-63 e1-3. 
20. Pacifico L, Bonci E, Di Martino M, et al. A double-blind, placebo-controlled 
randomized trial to evaluate the efficacy of docosahexaenoic acid supplementation on 
hepatic fat and associated cardiovascular risk factors in overweight children with 
nonalcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2015;25:734-41. 
21. Boyraz M, Pirgon O, Dundar B, et al. Long-Term Treatment with n-3 
Polyunsaturated Fatty Acids as a Monotherapy in Children with Nonalcoholic Fatty Liver 
Disease. J Clin Res Pediatr Endocrinol 2015;7:121-7. 
22. Ramon-Krauel M, Salsberg SL, Ebbeling CB, et al. A low-glycemic-load versus 
low-fat diet in the treatment of fatty liver in obese children. Child Obes 2013;9:252-60. 
23. Jin R, Le NA, Liu S, et al. Children with NAFLD are more sensitive to the 
adverse metabolic effects of fructose beverages than children without NAFLD. J Clin 
Endocrinol Metab 2012;97:E1088-98. 
24. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in 
an urban population in the United States: impact of ethnicity. Hepatology 2004;40:1387-
95. 
25. Mottin CC, Moretto M, Padoin AV, et al. The role of ultrasound in the diagnosis 
of hepatic steatosis in morbidly obese patients. Obes Surg. 2004;14:635-7. 
Copyright © ESPGHAN and NASPGHAN. All rights reserved.
26. Dowman JK, Tomlinson JW, Newsome PN. Systematic review: the diagnosis and 
staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment 
Pharmacol Ther 2011;33:525-40. 
27. Baxter KA, Ware RS, Batch JA, et al. Predicting success: factors associated with 
weight change in obese youth undertaking a weight management program. Obes Res Clin 
Pract 2013;7:e147-e54. 
28. Lozupone CA, Stombaugh JI, Gordon JI, et al. Diversity, stability and resilience 
of the human gut microbiota. Nature 2012;489:220-30. 
29. Scorletti E, Bhatia L, McCormick KG, et al. Effects of purified eicosapentaenoic 
and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome* 
study. Hepatology 2014;60:1211-21. 
30. St-Jules DE, Watters CA, Brunt EM, et al. Estimation of fish and omega-3 fatty 
acid intake in pediatric nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 
2013;57:627-33. 
31. Jin R, Welsh JA, Le NA, et al. Dietary fructose reduction improves markers of 
cardiovascular disease risk in Hispanic-American adolescents with NAFLD. Nutrients 
2014;6:3187-201. 
32. Burrows T, Golley RK, Khambalia A, et al. The quality of dietary intake 
methodology and reporting in child and adolescent obesity intervention trials: a 
systematic review. Obes Rev 2012;13:1125-38. 
33. Keating SE, Hackett DA, George J, Jet al. Exercise and non-alcoholic fatty liver 
disease: a systematic review and meta-analysis. J Hepatol 2012;57:157-66. 
34. Lee S, Bacha F, Hannon T, et al. Effects of aerobic versus resistance exercise 
without caloric restriction on abdominal fat, intrahepatic lipid, and insulin sensitivity in 
obese adolescent boys: a randomized, controlled trial. Diabetes 2012;61:2787-95. 
35. Lee S, Deldin AR, White D, et al. Aerobic exercise but not resistance exercise 
reduces intrahepatic lipid content and visceral fat and improves insulin sensitivity in 
obese adolescent girls: a randomized controlled trial. Am J Physiol Endocrinol Metab 
2013;305:E1222-9. 
36. Van Der Heijden GJ, Wang ZJ, Chu Z, et al. Strength exercise improves muscle 
mass and hepatic insulin sensitivity in obese youth. Med Sci Sports Exerc 2010;42:1973-
80. 
37. Van der Heijden GJ, Wang ZJ, Chu ZD, et al. A 12-week aerobic exercise 
program reduces hepatic fat accumulation and insulin resistance in obese, Hispanic 
adolescents. Obesity 2010;18:384-90. 
Copyright © ESPGHAN and NASPGHAN. All rights reserved.
38. Nobili V, Marcellini M, Devito R, et al. NAFLD in children: a prospective 
clinical-pathological study and effect of lifestyle advice. Hepatology 2006;44:458-65. 
39. Africa JA, Newton KP, Schwimmer JB. Lifestyle Interventions Including 
Nutrition, Exercise, and Supplements for Nonalcoholic Fatty Liver Disease in Children. 
Dig Dis Sci 2016;61:1375-86. 
 Legends: 
 
Figure 1: Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) 
flow diagram of study selection process for systematic literature review 
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TABLE 
Table 1: Summary of randomised control trials retrieved (n=15) 
Author 
(Year); 
Country 
Intervention [co-
intervention and 
Control] 
Age Range; 
Sample size 
(% male) 
Study 
Duration 
[Control] 
Outcome 
Measures 
Changes to Outcome Measures Post-
Intervention 
Vitamin E 
Vajro et al. 
(2004); Italy 
Oral α-
acetatetocopherol 
(400mg/d 2 months, 
100mg/d 3 months, 2 
month washout) [Low 
calorie diet (Italian 
Recommended 
Dietary Allowanced) + 
exercise] 
NR; 28 (75%) 7 months 
[Placebo] 
Primary: US, 
ALT 
Secondary: 
BMI 
Stratified results based on weight loss; 
1. Decrease BMI + vitamin E: improved liver 
echogenicity, ALTa 
2. Decrease BMI + placebo: improved liver 
echogenicity, ALTb 
3. Stable BMI + vitamin E: improved liver 
echogenicity, ALTb 
4. Stable BMI + placebo; No change ALT or 
liver echogenictya 
Nobili et al. 
(2006, 
2008); Italy 
Alpha-tocopherol 
(600ID/d) + Ascorbic 
Acid (500mg/d) [1 hr 
monthly nutritional 
counselling.  Hypo-/ 
Iso-caloric diet (Italian 
Recommended 
Dietary Allowance) + 
45min/day aerobic 
exercise] 
3-18; 90 
(32%) 
24 months 
[Placebo] 
Primary: 
NAS#, ALT, 
AST 
Secondary: 
Z-BMI, BMI, 
TG, TC, 
FSG, FI, 
HOMA-IR 
Primary:  NAFLD Activity Score,  ALT, AST 
in intervention and control b 
Secondary:  Z-BMI, BMI in intervention and 
control b FSG, FI, TC, TG, HOMA-IR in 
intervention and control b 
Wang et al. 
(2008); 
China 
Vitamin E (100mg/d) + 
low calorie diet + 
excercise/ aerobic 
exercise + reduced 
caloric intake/ no 
intervention [NA] 
10-17; 66 
(64%) 
1 month 
[Lifestyle 
control/ 
control] 
Primary: US, 
ALT, AST 
Secondary: 
Z-BMI, TG, 
TC, FSG, FI, 
HOMA  
Primary: No change to liver echogenicity b.  
ALT and AST in intervention group a 
Secondary:  Z-BMI, TG, TC, FI, FSG and 
HOMA-IR in intervention group a 
Akcam et 400IU/d Vitamin E 9-17; 67 (NR) 6 months Primary: US Primary:  steatosis in intervention and control 
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al. (2011); 
Turkey 
[Tailored dietary 
advice + 30 minutes 
aerobic PA/day] 
[Control] Secondary: 
BMI, TG, TC, 
FSG, FI, 
HOMA-IR 
a 
Secondary:  BMI in intervention a  TC, LDL, 
TG, HOMA-IR in intervention and control b No 
change FSG, FI in intervention and control b 
Lavine et 
al. (2011); 
USA 
RRR--tocopherol 
(800IU/d) [Uniform 
standard-of-care 
advice on diet and 
exercise at each visit 
by physicians and 
dietitians] 
8-17; 173 
(81%) 
120 weeks 
[Placebo] 
Primary: 
NAS#, ALT, 
AST, GGT, 
ALP 
Secondary: 
QOL, Z-BMI, 
BMI, BW, 
WC, TG, TC, 
FSG, HOMA-
IR, HDL, LDL 
Primary: Improved NAFLD Activity Score in 
intervention group a, ALT, AST, GGT, ALP in 
intervention and control b Resolution of NASH 
was significantly greater in children treated 
with vitamin E than placebo a 
Secondary: TG, BW, BMI, WC, QOL in 
intervention and control b  No change Z-BMI, 
FSH, HOMA-IR in intervention and control b 
TC, HDL, LDL in intervention and control b 
Probiotic 
Vajro et al. 
(2011); Italy 
Oral Lactobacillus 
rhamnosus strain GG 
(12 billion CFU/day) 
[NA] 
NR; 20 (90%) 8 weeks 
[Placebo] 
Primary: US, 
ALT, AST 
Secondary: 
TG, TC, Z-
BMI 
Primary: No change in liver echogenicity, AST 
in both groups. ALT in intervention group a 
Secondary: No change to secondary outcome 
measures in both groups 
Alisi et al. 
(2014); Italy  
2 sachets VSL#3/day  
[Low Calorie Diet 
(Italian Recommended 
Dietary Allowances) + 
aerobic exercise (3 x 
30-40 mins/week)] 
NR; 44 (55%) 4 months 
[Placebo] 
Primary: US, 
ALT 
Secondary: 
TG, HOMA, 
BMI 
Primary:  risk of severe NASH (OR 0.001) a. 
 ALT in intervention and control b 
Secondary:  TG, HOMA in intervention and 
control b  BMI in intervention group a 
Omega-3 Fatty Acids 
Nobili et al. 
(2011, 
2013); Italy 
250mg vs. 500mg 
DHA/day [Low calorie 
diet] 
<18 years; 60 
(42%) 
24 months 
[Placebo 
290mg/day 
linolenic acid] 
Primary: US, 
ALT 
Secondary: 
HOMA-IR, 
BMI, TG 
Primary:  risk of severe steatosis (250mg = 
OR 0.01/ 500mg = OR 0.04) a,  ALT with no 
difference between dosages a 
Secondary:  TG, BMI, HOMA-IR with no 
difference between dosages a,  BMI in 
intervention and controls b 
Bohraz et 1000mg/day omega-3 9-17; 108 12 months Primary: US, Primary:  steatosis, ALT and AST in both 
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al. (2015); [American Heart 
Association diet (50% 
CHO, 20% protein, 
30% fat) with reduced 
caloric intake and PA 
3 times a week with 
intention for weight 
loss] 
(51%) [Placebo] ALT, AST 
Secondary: 
BMI, HDL-C, 
TG, TC, FI, 
FG, IS, 
HOMA-IR, 
SBP  
intervention and control groups a
Secondary:  HDL-C a, TG, FI and HOMA-IR 
a,  BMI in intervention and control groups b,  
SBP in intervention group a 
Janczyk et 
al. (2015) 
450-1300mg/day 3:2 
DHA:EPA [Individually 
prescribed diet in 
conjunction with 
increased PA with 
intention of weight 
loss] 
>5 and <19; 
76 (86%) 
6 months 
[Placebo 
omega-6 
sunflower oil] 
Primary: 
ALT, AST, 
GGT 
Secondary: 
FSG, FI, 
HOMA-IR, 
adiponectin, 
cholesterol, 
steatosis 
(US), BMI, 
WC 
Primary:  ALT levels in intervention and 
control b 
Secondary:  AST and GGT  a  adiponectin in 
omega-3 group a .  No changes in ALT, 
steatosis, FSG, FI, HOMA-IR, BMI z-score or 
WC z-score b 
Pacifico et 
al. (2015) 
250mg/day DHA [Low 
calorie diet (Italian 
Recommended 
Dietary Allowanced) + 
60 mins PA 5 times a 
week] 
<18 years; 51 
(59%) 
6 months 
[Placebo 
290mg/day 
linoleic acid] 
Primary: 
Hepatic fat 
(MRS), ALT 
Secondary: 
TG, Z-BMI, 
FI, HOMA-IR 
Primary:  Hepatic fat by MRS in intervention 
group a  ALT in intervention group b 
Secondary:  FI, TG a,  BMI, BMI-SDS, FI, 
HOMA-IR in intervention group b 
Dietary Modification 
Ramon-
Krauel et al. 
(2013); 
USA 
Low Glycemic Load 
diet [nutritional 
education, exercise, 
grocery lists, food 
preparation 
demonstrations] 
7-18; 17 
(82%) 
6 months 
[Conventional 
low fat diet] 
Primary: 
Hepatic Fat 
(MRS), ALT, 
AST 
Secondary: 
BMI, HDL, 
LDL, TG, FI, 
FSG, HOMA-
Primary:  hepatic fat (%), ALT, AST in 
intervention and control b 
Secondary:  BMI, FI, FSG, HOMA-IR, LDL, 
HDL, TG in intervention and control b 
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a: statistically significantly difference when compared to the control 
b: no statistical difference between intervention and control 
*: VSL#3 is eight strains of probiotics (Streptococcus thermophilus, bifidobacteria [B. breve, B. infantis, B. longum], Lactobacillus 
acidophilus, L. plantarum, L. paracasei and L. delbrueckii subsp. bulgaricus) 
#: NAFLD Activity Score is a numerical score of NAFLD severity [sum of separate scores for steatosis (0-3), hepatocellular ballooning 
(0-2) and lobular inflammation (0-2)] 
Abbreviations: ALP = alkaline phosphatase; ALT = alanine transaminase; AST = aspartate transaminase; BMI = body mass index; 
CFU = colony forming units; CHO = carbohydrate; DHA = docosahexanoic acid; FI = fasting insulin; FSG = fasting serum glucose; 
GGT = gamma-glutamyl transpeptidase; HDL = high density lipoprotein; HOMA-IR = homeostatic model assessment of insulin 
resistance; IU = international units; LDL = low density lipoprotein; LV = left ventricular function; NA = not available; OR = odds ration; 
MRS = magnetic resonance spectroscopic imaging; NAS = NAFLD activity score; NR = not reported; NRT = non-randomised control 
trial; PA = physical activity; QOL = quality of life; RCT = randomised control trial; SBP = systolic blood pressure; TC = total 
cholesterol; TG = triglycerides; US = ultrasound; VAT = visceral adipose tissue; WC = waist circumference; Z-BMI = BMI Z-score. 

IR 
Jin et al. 
(2014); 
USA 
Consumption of 3 x 
8floz bottles/d (33g 
glucose/bottle) [no 
change to diet or 
physical activity] 
11-18; 21 
(52%) 
4 weeks 
[Consumption 
of 3 x 8floz 
bottles/d (33g 
fructose/ 
bottle)] 
Primary: 
Hepatic Fat 
(MRS), ALT, 
AST 
Secondary: 
BW, TG, FI, 
HOMA-IR, 
FFA, LDL 
Primary: No change to hepatic fat (%), ALT, 
AST in intervention and control b 
Secondary:  HOMA-IR, plasma FFA, LCL, FI 
in intervention group a No change in BW, TG 
in intervention and control b 
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Table 2: Quality rating and risk of bias determined using the American Dietetic Association 
Quality Criteria Checklist 
Theme Author Validity Questions1 Overall Quality 
Rating 1 2 3 4 5 6 7 8 9 10 
Vitamin E Nobili (2006)           Neutral 
Nobili (2008)           Neutral 
Lavine(2011)           Positive 
Vajro (2004)           Neutral 
Wang (2008)           Negative 
Ackam (2011)           Neutral 
Probiotics Vajro (2011)           Neutral 
Alisi (2014)           Neutral 
Omega-3 Nobili (2010)           Positive 
Nobili (2013)           Positive 
Boyraz (2015)           Neutral 
Janczyk (2015)           Neutral 
Pacifico (2015)           Positive 
Low Glycaemic Load Diet Ramon-Krauel (2013)           Neutral 
Fructose Jin (2014)           Neutral 
 
 Low Risk of Bias    Risk of Bias 
 
1Validity Questions: 1) Clear Research Question; 2) Unbiased Selection Of Participants; 3) Randomization/ 
Group Comparability; 4) Description Of Withdrawals; 5) Blinding; 6) Study Procedures Described; 7) Clearly 
Defined Outcomes; 8) Appropriate Statistical Analysis; 9) Results Support Conclusion; 10) Funding Or 
Sponsorship Bias Unlikely 
 

